China
# |
Name |
Goodwill |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 591.49 M
|
Dec. 31, 2023 | USD 0.77 | -3.24% |
|
China |
|
2 |
USD 493.58 M
|
Dec. 31, 2023 | USD 1.43 | -2.45% |
|
China |
|
3 |
USD 391.69 M
|
Dec. 31, 2023 | USD 1.81 | -1.42% |
|
China |
|
4 |
USD 389.34 M
|
Dec. 31, 2023 | USD 3.70 | -0.36% |
|
China |
|
5 |
USD 256.47 M
|
Dec. 31, 2023 | USD 7.19 | 0.25% |
|
China |
|
6 |
USD 235.58 M
|
Dec. 31, 2023 | USD 1.82 | 0.98% |
|
China |
|
7 |
USD 97.54 M
|
Dec. 31, 2023 | USD 0.48 | -2.61% |
|
China |
|
8 |
USD 78.12 M
|
Dec. 31, 2023 | USD 1.77 | 0.45% |
|
China |
|
9 |
USD 58.25 M
|
Dec. 31, 2023 | USD 7.82 | 0.44% |
|
China |
|
10 |
USD 42.42 M
|
Dec. 31, 2023 | USD 5.28 | -0.15% |
|
China |
|
11 |
USD 40.81 M
|
Dec. 31, 2023 | USD 0.41 | -0.43% |
|
China |
|
12 |
USD 37.13 M
|
Dec. 31, 2023 | USD 3.07 | 0.49% |
|
China |
|
13 |
USD 23.65 M
|
Dec. 31, 2023 | USD 1.01 | 0.04% |
|
China |
|
14 |
USD 22.02 M
|
Dec. 31, 2023 | USD 6.71 | 0.24% |
|
China |
|
15 |
USD 21.66 M
|
Dec. 31, 2023 | USD 0.94 | -0.82% |
|
China |
|
16 |
USD 20.84 M
|
Dec. 31, 2023 | USD 0.36 | 3.69% |
|
China |
|
17 |
USD 20.59 M
|
Dec. 31, 2023 | USD 10.27 | -0.41% |
|
China |
|
18 |
USD 20.37 M
|
Dec. 31, 2023 | USD 0.23 | 9.73% |
|
China |
|
19 |
USD 19.16 M
|
Dec. 31, 2023 | USD 1.08 | -3.01% |
|
China |
|
20 |
USD 17.92 M
|
Dec. 31, 2023 | USD 1.36 | -2.06% |
|
China |
|
21 |
USD 16.73 M
|
Dec. 31, 2023 | USD 2.15 | -0.60% |
|
China |
|
22 |
USD 15.69 M
|
Dec. 31, 2023 | USD 3.07 | 0.63% |
|
China |
|
23 |
USD 13.75 M
|
Dec. 31, 2023 | USD 3.31 | 1.64% |
|
China |
|
24 |
USD 8.31 M
|
Dec. 31, 2023 | USD 4.55 | -4.49% |
|
China |
|
25 |
USD 7.35 M
|
Dec. 31, 2023 | USD 3.37 | -1.70% |
|
China |
|
26 |
USD 6.78 M
|
Dec. 31, 2023 | USD 52.19 | 2.06% |
|
China |
|
27 |
USD 6.64 M
|
Dec. 31, 2023 | USD 5.36 | -0.25% |
|
China |
|
28 |
USD 3.85 M
|
Dec. 31, 2023 | USD 0.89 | -0.25% |
|
China |
|
29 |
USD 3.67 M
|
Dec. 31, 2023 | USD 4.81 | -0.80% |
|
China |
|
30 |
USD 3.48 M
|
Dec. 31, 2023 | USD 4.36 | -3.02% |
|
China |
|
31 |
USD 3.08 M
|
Dec. 31, 2023 | USD 0.94 | 0.80% |
|
China |
|
32 |
USD 2.51 M
|
Dec. 31, 2023 | USD 0.24 | 1.60% |
|
China |
|
33 |
USD 2.35 M
|
Dec. 31, 2023 | USD 1.52 | 0.54% |
|
China |
|
34 |
USD 1.89 M
|
Dec. 31, 2023 | USD 1.13 | 1.02% |
|
China |
|
35 |
USD 1.34 M
|
Dec. 31, 2023 | USD 0.15 | 2.66% |
|
China |
|
36 |
USD 440.11 K
|
Dec. 31, 2023 | USD 0.71 | -2.83% |
|
China |
|
37 |
USD 188.72 K
|
Dec. 31, 2023 | USD 1.33 | 1.17% |
|
China |
|
38 |
USD 161.98 K
|
Dec. 31, 2023 | USD 0.79 | 7.30% |
|
China |
|
39 |
USD 0.00
|
Dec. 31, 2023 | USD 6.68 | -1.47% |
|
China |
|
40 |
USD 0.00
|
Dec. 31, 2023 | USD 0.97 | 0.21% |
|
China |
|
41 |
USD 0.00
|
Dec. 31, 2023 | USD 1.02 | -3.77% |
|
China |
|
42 |
USD 0.00
|
Dec. 31, 2023 | USD 2.63 | -0.26% |
|
China |
|
43 |
USD 0.00
|
Dec. 31, 2023 | USD 0.73 | -4.26% |
|
China |
|
44 |
USD 0.00
|
Dec. 31, 2023 | USD 0.18 | -3.42% |
|
China |
|
45 |
USD 0.00
|
Dec. 31, 2023 | USD 0.30 | -0.45% |
|
China |
|
46 |
USD 0.00
|
Dec. 31, 2023 | USD 3.82 | 2.92% |
|
China |
|
47 |
USD 0.00
|
Dec. 31, 2023 | USD 0.66 | -1.16% |
|
China |
|
48 |
USD 0.00
|
Dec. 31, 2023 | USD 0.52 | -0.26% |
|
China |
|
49 |
USD 0.00
|
Dec. 31, 2023 | USD 4.24 | 0.13% |
|
China |
|
50 |
USD 0.00
|
Dec. 31, 2023 | USD 0.24 | 0.51% |
|
China |
The Clinical Trials company in China with the highest Goodwill is 3SBio Inc. (HKSE: 1530.HK) at USD 591.49 M.
The Clinical Trials company in China with the lowest Goodwill is Adagene Inc. (NasdaqGM: ADAG) at USD 0.00.
The top 10 Clinical Trials companies in China by Goodwill are 3SBio Inc., Lepu Medical Technology (Beijing) Co., Ltd., Pharmaron Beijing Co., Ltd., Hangzhou Tigermed Consulting Co., Ltd., WuXi AppTec Co., Ltd., Beijing Strong Biotechnologies, Inc., Tianjin Chase Sun Pharmaceutical Co.,Ltd, GuiZhou SanLi Pharmaceutical Co.,Ltd, Betta Pharmaceuticals Co., Ltd. and Shanghai Haoyuan Chemexpress Co., Ltd..
The bottom 10 Clinical Trials companies in China by Goodwill are Adagene Inc., RemeGen Co., Ltd., Alphamab Oncology, Hangzhou Biotest Biotech Co.,Ltd., Beijing Kawin Technology Share-Holding Co., Ltd., HOB Biotech Group Corp.,Ltd, Shanghai Allist Pharmaceuticals Co., Ltd., Chengdu Easton Biopharmaceuticals Co., Ltd., Jiangsu Bioperfectus Technologies Co., Ltd. and Shenzhen Chipscreen Biosciences Co., Ltd..